Novo Nordisk A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novo Nordisk A/S
US FTC sends notices to more than 700 companies about penalties they will face if they use deceptive endorsements and testimonials to promote their products. Industry experts discuss impact of surprising action and cautions to take in teaming up with influencers.
The formal split between the companies had been in the works since January, with 2seventy set to take over oncology operations while bluebird focuses on gene therapies.
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.
- Large Molecule
- Other Names / Subsidiaries
- Corvidia Therapeutics
- Neose Technologies, Inc.
- Novo Holdings A/S
- Novo Nordisk Pharmaceuticals, Inc.
- Pharmaero Aps
- Xellia Pharmaceuticals ApS
- Ziylo Ltd